Investment Rating - The industry maintains an "Overweight" rating, suggesting a positive outlook for investment opportunities in the sector [5]. Core Insights - The market performance for the Chinese medicine sector showed a slight decline of 1.67% last week, which is relatively smaller compared to other pharmaceutical segments [1]. - The price-to-earnings (PE) ratio for the Chinese medicine sector is reported at 26.63X, with a slight decrease of 0.45X week-on-week, indicating a valuation within the historical range [2]. - The demand for tonic herbs continues to grow, leading to a slight increase in the Chinese medicinal herb price index, which rose by 0.1% last week [3]. - The integration of Chinese medicinal pieces into a national drug traceability code system is accelerating, which is expected to enhance the quality and management of the industry [4]. Summary by Sections Market Performance - The Chinese medicine sector index closed at 6234.32 points, down 1.67% last week, while the overall pharmaceutical sector index fell by 2.06% [1][11]. - Notable companies with strong performance include Wanbangde, Tianmu Pharmaceutical, and Guhang Medicine, while underperformers include *ST Changyao and ST Hulahua [1][17]. Valuation - The current PE ratio for the Chinese medicine sector is 26.63X, with a year-to-date maximum of 30.26X and a minimum of 24.72X [2]. - The price-to-book (PB) ratio stands at 2.24X, with a year-to-date maximum of 2.52X and a minimum of 2.17X [2]. Industry Trends - The demand for tonic herbs is on the rise, contributing to a slight increase in the price index for Chinese medicinal herbs [3]. - The national drug traceability system for Chinese medicinal pieces is being implemented, which is expected to improve the quality and traceability of medicinal materials [4]. Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [5]. - Specific investment targets include companies with strong R&D capabilities, unique products, and those less affected by price reductions due to centralized procurement [9].

Core Viewpoint - The company, Shouxiangu, is a pioneer in applying aerospace breeding technology to the cultivation of rare Chinese medicinal materials, with over 20 years of practical experience [1] Group 1: Company Achievements - As of December 30, 2025, the company has collaborated with national-level aerospace projects seven times, successfully sending seeds or strains of rare medicinal materials such as Ganoderma and Dendrobium into space [1] - The company has developed excellent new varieties, including "XianZhi No. 2" and "XianHua No. 3" of Ganoderma and Dendrobium [1] Group 2: Strategic Focus - The company adheres to a "research-driven enterprise" strategy, establishing a comprehensive research and innovation platform across the entire industry chain [1] - The integration of aerospace technology with traditional Chinese medicine wisdom is a key focus for the company [1] Group 3: Future Outlook - The company aims to continue leveraging technological innovation as a driving force to explore more possibilities for commercial aerospace technology in the traditional Chinese medicine industry [1] - The goal is to provide higher quality health products for consumers and create long-term value for investors [1]

Group 1 - The core viewpoint of the news is that Zhejiang Shouxiangu Pharmaceutical Co., Ltd. has shown a stock price increase of 1.24%, reaching 19.56 CNY per share, with a total market capitalization of 3.878 billion CNY [1] - The company specializes in the breeding, cultivation, processing, and sales of precious Chinese medicinal materials, including Ganoderma lucidum and Dendrobium officinale, with its main business revenue composition being 71.92% from Ganoderma spore powder products, 15.57% from Dendrobium products, and 10.88% from other sources [1] Group 2 - Among the top ten circulating shareholders of Shouxiangu, the Rongtong Health Industry Flexible Allocation Mixed A/B fund has increased its holdings by 82,300 shares in the third quarter, now holding 1.2823 million shares, which accounts for 0.65% of the circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund has a current scale of 1.816 billion CNY, with a year-to-date return of 9.15% and a one-year return of 4.6% [2] Group 3 - The fund manager of Rongtong Health Industry Flexible Allocation Mixed A/B is Wan Minyuan, who has a total fund asset scale of 5.957 billion CNY, with the best fund return during his tenure being 132.72% and the worst being -25.09% [3]

Meeting Overview - The second extraordinary general meeting of shareholders was held on December 23, 2025, at the company's location in Zhejiang Province [2] - The meeting was convened by the board of directors, with the chairman, Mr. Li Mingyan, presiding over the meeting [2][3] - The meeting was witnessed by lawyers from Zhejiang Tiance Law Firm, ensuring compliance with legal and regulatory requirements [7] Attendance and Voting - A total of 9 directors were present, with 7 attending the meeting; two directors were absent due to official duties [3] - The voting process adhered to the Company Law and the company's articles of association, with all resolutions passed in accordance with the required majority [2][4] Resolutions Passed - The following proposals were approved during the meeting: 1. The 2026 annual routine related party transaction plan [4] 2. The application for a comprehensive credit limit and related guarantee matters for 2026 [4] 3. The use of temporarily idle raised funds and self-owned funds for cash management in 2026 [5] 4. The revision of the remuneration management system for directors and senior management [5] - Proposal 2 was classified as a special resolution, requiring approval from more than two-thirds of the voting rights held by shareholders present [5][6] Legal Opinion - The legal opinion provided by the witnessing lawyers confirmed that the meeting's procedures, participant qualifications, and voting processes complied with relevant laws and regulations [7]

Core Viewpoint - Shouxiangu announced the approval of multiple proposals at its 2025 second extraordinary general meeting, including the 2026 annual related party transaction plan and the application for the 2026 comprehensive credit limit and related guarantee matters [1] Group 1 - The company held its 2025 second extraordinary general meeting on December 23 [1] - The meeting approved the proposal for the 2026 annual related party transaction plan [1] - The company also approved the proposal regarding the application for the 2026 comprehensive credit limit and related guarantee matters [1]

浙江寿仙谷医药股份有限公司 2025 年第二次投资者接待日活动召开情况 为进一步提高企业治理水平，增进公司与广大投资者之间的信息沟通，公司 2025 年第二次投资者接待日活动于 2025 年 12 月 23 日举行，公司组织投资者们 参观了寿仙谷有机国药基地、洋垄厂区（未来工厂+生物育种创新中心）及寿仙 谷文化馆，管理层就公司经营情况、科研进展等与广大投资者进行了充分交流， 同时解答了投资者较为关注的问题。具体情况如下： 一、活动基本情况 1、活动时间：2025 年 12 月 23 日 2、活动地点： （1）上午：公司基地—寿仙谷有机国药养生园；洋垄厂区—未来工厂+生物 育种创新中心 二、活动主要交流情况 1、核心产品省外营销拓展情况，以及公司对行业的发展情况的判断 答：公司在省外的业务拓展主要围绕去壁灵芝孢子粉核心产品的推广与销售。今年通过 省外渠道经销商和品牌加盟商两种模式进行渠道拓展。 从当前的宏观形势看，医药内需板块在未来一两年内整体情况将继续保持一定的复苏压 力。随着国家进入高质量发展，人民群众日益追求高水平健康的趋势不会变，中国进入银发 经济时代，中医药的功效被越来越多的人接受和认可的现实不会变， ...

| | | 债券代码：113660 债券简称：寿 22 转债 浙江寿仙谷医药股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 二、 议案审议情况 审议结果：通过 表决情况： | 股东类型 | 同意 | | 反对 | | 弃权 | | | --- | --- | --- | --- | --- | --- | --- | | | 票数 | 比例（%） | 票数 | 比例 （%） | 票数 | 比例 （%） | | A 股 | 3,798,315 | 92.8616 | 226,721 | 5.5429 | 65,260 | 1.5955 | 2、 议案名称：关于公司申请 2026 年度综合授信额度及相关担保事项的议案 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 218 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 75,843,185 | | 3、出席会议的股东所持有表决权股 ...

下 天册律师事务所 T T & C L A W F L R M 法律意见书 浙江天册律师事务所 关于 浙江寿仙谷医药股份有限公司 2025 年第二次临时股东会的 法律意见书 天册律师事务所 T & C LAW FIRM 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话: 0571-87901111 传真: 0571-87901500 2025 2025 1 12 23 2025 12 23 9:15-9:25 9:30-11:30 13:00-15:00 2025 12 23 9:15-15:00 2025 2025 11 29 1. 2026 2. 2026 3. 2026 4. < > 1 2 3 4 2 16 73,471,077 37.0610 % 202 2,372,108 1.1966% 1. 2026 3,798,315 226,721 65,260 92.8616% 2. 2026 75,518,704 271,021 53,460 99.5721% 3. 2026 75,435,464 349,981 57,740 99.4624% 3 4. < > 75,502 ...

Group 1 - The company, Shouxiangu (603896), has entered Alibaba International Station and Amazon platforms but has not yet achieved direct product exports to EU countries [1] - The company will fulfill its information disclosure obligations in a timely manner if there are significant developments in its international business [1]

Group 1 - The company, Shouxiangu (603896), has stated that its main online sales platforms include Tmall, JD.com, its official website, Shouxiangu official mall (WeChat), Douyin, and Kuaishou [1] - The company has not disclosed the sales proportion from each major platform [1]